Related references
Note: Only part of the references are listed.Biomarkers Associated With Response to Regorafenib in Patients With Hepatocellular Carcinoma
Michael Teufel et al.
GASTROENTEROLOGY (2019)
Influence of CYP3A4/5 and ABC transporter polymorphisms on lenvatinib plasma trough concentrations in Japanese patients with thyroid cancer
Tomoko Ozeki et al.
SCIENTIFIC REPORTS (2019)
Ribociclib in HR+/HER2-Advanced or Metastatic Breast Cancer Patients
Kaitlin Rascon et al.
ANNALS OF PHARMACOTHERAPY (2019)
Associations among regorafenib concentrations, severe adverse reactions, and ABCG2 and OATP1B1 polymorphisms
Akimitsu Maeda et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2019)
Systemic Therapy for Advanced Hepatocellular Carcinoma in an Evolving Landscape
Kabir Mody et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2019)
Second-line Treatments of Advanced Hepatocellular Carcinoma Systematic Review and Network Meta-Analysis of Randomized Controlled Trials
Ziad Bakouny et al.
JOURNAL OF CLINICAL GASTROENTEROLOGY (2019)
Monitoring serum proangiogenic cytokines from hepatocellular carcinoma patients treated with sorafenib
Takuya Adachi et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2019)
Haemophagocytic lymphohistiocytosis complicating pembrolizumab treatment for metastatic breast cancer in a patient with the PRF1A91V gene polymorphism
Hanny Al-Samkari et al.
JOURNAL OF MEDICAL GENETICS (2019)
Association of PD-L1 gene rs4143815 C > G polymorphism and human cancer susceptibility: A systematic review and meta-analysis
Ju Zou et al.
PATHOLOGY RESEARCH AND PRACTICE (2019)
Lenvatinib - A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer
Yvonne Hewett et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2018)
PD-1 and cancer: molecular mechanisms and polymorphisms
Arash Salmaninejad et al.
IMMUNOGENETICS (2018)
Chemotherapy for hepatocellular carcinoma: current status and future perspectives
Masafumi Ikeda et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2018)
Association between single-nucleotide polymorphisms and adverse events in nivolumab-treated non-small cell lung cancer patients
Sander Bins et al.
BRITISH JOURNAL OF CANCER (2018)
FDA Approval: Ribociclib for the Treatment of Postmenopausal Women with Hormone Receptor-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Anand Shah et al.
CLINICAL CANCER RESEARCH (2018)
Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand-Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib
Mitsukuni Suenaga et al.
CLINICAL COLORECTAL CANCER (2018)
Host genetic profiling to increase drug safety in colorectal cancer from discovery to implementation
Erika Cecchin et al.
DRUG RESISTANCE UPDATES (2018)
Lenvatinib in the management of metastatic renal cell carcinoma: a promising combination therapy?
Delia De Lisi et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2018)
Lenvatinib for the treatment of renal cell carcinoma
Giandomenico Roviello et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2018)
Ribociclib for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer
Howard A. Burris
EXPERT REVIEW OF ANTICANCER THERAPY (2018)
Lenvatinib and its use in the treatment of unresectable hepatocellular carcinoma
Mark A. Baxter et al.
FUTURE ONCOLOGY (2018)
Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial
Masatoshi Kudo et al.
LANCET (2018)
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
Andrew X. Zhu et al.
LANCET ONCOLOGY (2018)
Tivantinib for second-line treatment of MET-high, advanced hepatocellular carcinoma (METIV-HCC): a final analysis of a phase 3, randomised, placebo-controlled study
Lorenza Rimassa et al.
LANCET ONCOLOGY (2018)
Cabozantinib in Patients with Advanced and Progressing Hepatocellular Carcinoma
G. K. Abou-Alfa et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Ribociclib plus letrozole and concomitant palliative radiotherapy for metastatic breast cancer
Icro Meattini et al.
BREAST (2018)
In vitro UGT1A1 inhibition by tyrosine kinase inhibitors and association with drug-induced hyperbilirubinemia
Hisham Qosa et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2018)
PD-L1 rs2282055 is associated with opposite treatment effect between platinum-based chemotherapy and nivolumab treatment
Takashi Nomizo et al.
CANCER RESEARCH (2018)
Lenvatinib as a therapy for unresectable hepatocellular carcinoma
Andrea Spallanzani et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2018)
Multicenter prospective study of angiogenesis polymorphism validation in HCC patients treated with sorafenib. An INNOVATE study protocol
Andrea Casadei Gardini et al.
TUMORI JOURNAL (2018)
Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
Giorgia Marisi et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2018)
Systemic Therapy for Hepatocellular Carcinoma: Latest Advances
Masatoshi Kudo
CANCERS (2018)
The new era of precision medicine in hepatocellular carcinoma: the urgent need for promising biomarkers
Haruhiko Takeda et al.
HEPATOBILIARY SURGERY AND NUTRITION (2018)
Treatment of advanced hepatocellular carcinoma: immunotherapy from checkpoint blockade to potential of cellular treatment
Elaine Hon-Lam Siu et al.
TRANSLATIONAL GASTROENTEROLOGY AND HEPATOLOGY (2018)
Update on hepatocellular carcinoma from the 2018 Gastrointestinal Cancer Symposium (ASCO GI)
Victor Hugo Fonseca de Jesus et al.
JOURNAL OF HEPATOCELLULAR CARCINOMA (2018)
Specific CYP450 Genotypes in the Chinese Population Affect Sorafenib Toxicity in HBV/HCV-associated Hepatocellular Carcinoma Patients
Guo Xing Gang et al.
BIOMEDICAL AND ENVIRONMENTAL SCIENCES (2018)
Updates on managing advanced breast cancer with palbociclib combination therapy
Teresa M. McShane et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer
Marc Thill et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Ribociclib with letrozole vs letrozole alone in elderly patients with hormone receptor-positive, HER2-negative breast cancer in the randomized MONALEESA-2 trial
Gabe S. Sonke et al.
BREAST CANCER RESEARCH AND TREATMENT (2018)
US Food and Drug Administration Approval: Cabozantinib for the Treatment of Advanced Renal Cell Carcinoma
Harpreet Singh et al.
CLINICAL CANCER RESEARCH (2017)
Clinical Pharmacokinetics and Pharmacodynamics of Cabozantinib
Steven A. Lacy et al.
CLINICAL PHARMACOKINETICS (2017)
New chemical treatment options in second-line hepatocellular carcinoma: what to do when sorafenib fails?
Hyun Young Woo et al.
EXPERT OPINION ON PHARMACOTHERAPY (2017)
Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib: a systematic-review and meta-analysis of the impact on survival
Omar Abdel-Rahman et al.
EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2017)
Phase II randomised discontinuation trial of cabozantinib in patients with advanced solid tumours
Patrick Schoffski et al.
EUROPEAN JOURNAL OF CANCER (2017)
Clinical Pharmacokinetic and Pharmacodynamic Profile of Lenvatinib, an Orally Active, Small-Molecule, Multitargeted Tyrosine Kinase Inhibitor
Ziad Hussein et al.
EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS (2017)
Regorafenib as treatment for patients with advanced hepatocellular cancer
Kiruthikah Thillai et al.
FUTURE ONCOLOGY (2017)
Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma
Min-Kyung Yeo et al.
HUMAN PATHOLOGY (2017)
Association between ABCG2 and SLCO1B1 polymorphisms and adverse drug reactions to regorafenib: a preliminary study
Akimitsu Maeda et al.
INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS (2017)
Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses
Toshiyuki Tamai et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma: Analysis of two phase III studies
Jordi Bruix et al.
JOURNAL OF HEPATOLOGY (2017)
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial
Jordi Bruix et al.
LANCET (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
UGT1A polymorphisms as genetic biomarkers for hepatocellular carcinoma risk in Caucasian population
Elena De Mattia et al.
LIVER INTERNATIONAL (2017)
Palbociclib induces activation of AMPK and inhibits hepatocellular carcinoma in a CDK4/6-independent manner
Feng-Shu Hsieh et al.
MOLECULAR ONCOLOGY (2017)
PharmGKB summary: sorafenib pathways
Li Gong et al.
PHARMACOGENETICS AND GENOMICS (2017)
Palbociclib: A Review in HR-Positive, HER2-Negative, Advanced or Metastatic Breast Cancer
Esther S. Kim et al.
TARGETED ONCOLOGY (2017)
Sorafenib: A Review in Hepatocellular Carcinoma
Gillian M. Keating
TARGETED ONCOLOGY (2017)
Genetic biomarkers for hepatocellular cancer risk in a caucasian population
Elena De Mattia et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2017)
Clinical Impact of Single Nucleotide Polymorphism in PD-L1 on Response to Nivolumab for Advanced Non-Small-Cell Lung Cancer Patients
Takashi Nomizo et al.
SCIENTIFIC REPORTS (2017)
Clinical use of lenvatinib in combination with everolimus for the treatment of advanced renal cell carcinoma
Alessandro Leonetti et al.
THERAPEUTICS AND CLINICAL RISK MANAGEMENT (2017)
The role of ethnicity in personalized dosing of small molecule tyrosine kinase inhibitors used in oncology
Josephine A. Touma et al.
TRANSLATIONAL CANCER RESEARCH (2017)
Ang-2 polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib.
Giorgia Marisi et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
PALOMA-3: Phase III Trial of Fulvestrant With or Without Palbociclib in Premenopausal and Postmenopausal Women With Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer That Progressed on Prior Endocrine Therapy-Safety and Efficacy in Asian Patients
Hiroji Iwata et al.
JOURNAL OF GLOBAL ONCOLOGY (2017)
Interindividual and interethnic variability in drug disposition: polymorphisms in organic anion transporting polypeptide 1B1 (OATP1B1; SLCO1B1)
Hannah H. Lee et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study
Mahamadou Tandia et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2017)
Cabozantinib in hepatocellular carcinoma: results of a phase 2 placebo-controlled randomized discontinuation study
R. K. Kelley et al.
ANNALS OF ONCOLOGY (2017)
Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma
Masafumi Ikeda et al.
CLINICAL CANCER RESEARCH (2016)
Population pharmacokinetic analysis of lenvatinib in healthy subjects and patients with cancer
Anubha Gupta et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma
Willy Hugo et al.
CELL (2016)
Evaluation of the pharmacokinetics and metabolism of pembrolizumab in the treatment of melanoma
Teresa C. Longoria et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
An update on the pharmacodynamics, pharmacokinetics, safety and clinical efficacy of nivolumab in the treatment of solid cancers
Ashley C. Y. Wong et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2016)
Systemic treatment of hepatocellular carcinoma: why so many failures in the development of new drugs?
Maria Pia Brizzi et al.
EXPERT REVIEW OF ANTICANCER THERAPY (2016)
Lipiodol Transarterial Chemoembolization for Hepatocellular Carcinoma: A Systematic Review of Efficacy and Safety Data
Riccardo Lencioni et al.
HEPATOLOGY (2016)
Angiogenesis polymorphisms profile in the prediction of clinical outcome of advanced HCC patients receiving sorafenib: Combined analysis of VEGF and HIF-1α-Final results of the ALICE-2 study.
Luca Faloppi et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study
Jorge A. Marrero et al.
JOURNAL OF HEPATOLOGY (2016)
Regorafenib induced severe toxic hepatitis: characterization and discussion
Anne Sacre et al.
LIVER INTERNATIONAL (2016)
Targeting the RB-E2F pathway in breast cancer
J. Johnson et al.
ONCOGENE (2016)
Polymorphisms in SLCO1B1 and UGT1A1 are associated with sorafenib-induced toxicity
Sander Bins et al.
PHARMACOGENOMICS (2016)
PD-1 Pathway Inhibitors: Immuno-Oncology Agents for Restoring Antitumor Immune Responses
Patrick J. Medina et al.
PHARMACOTHERAPY (2016)
Stereoselective hydroxylation by CYP2C19 and oxidation by ADH4 in the in vitro metabolism of tivantinib
Yumi Nishiya et al.
XENOBIOTICA (2016)
eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib: final results of the ePHAS study
Andrea Casadei Gardini et al.
ONCOTARGET (2016)
Angiogenesis genotyping and clinical outcome during regorafenib treatment in metastatic colorectal cancer patients
Riccardo Giampieri et al.
SCIENTIFIC REPORTS (2016)
Hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS DISEASE PRIMERS (2016)
Palbociclib (PD0332991)-a Selective and Potent Cyclin-Dependent Kinase Inhibitor A Review of Pharmacodynamics and Clinical Development
Amy S. Clark et al.
JAMA ONCOLOGY (2016)
Metastatic Hepatocellular Carcinoma Responsive to Pembrolizumab
Phu Truong et al.
CUREUS JOURNAL OF MEDICAL SCIENCE (2016)
Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date
Daniel Pievsky et al.
JOURNAL OF HEPATOCELLULAR CARCINOMA (2016)
Regorafenib Is Transported by the Organic Anion Transporter 1B1 and the Multidrug Resistance Protein 2
Hiroki Ohya et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2015)
Hepatocellular Shuttling and Recirculation of Sorafenib-Glucuronide Is Dependent on Abcc2, Abcc3, and Oatp1a/1b
Aksana Vasilyeva et al.
CANCER RESEARCH (2015)
Phase I study of tivantinib in Japanese patients with advanced hepatocellular carcinoma: Distinctive pharmacokinetic profiles from other solid tumors
Takuji Okusaka et al.
CANCER SCIENCE (2015)
FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor-Positive, HER2-Negative Metastatic Breast Cancer
Julia A. Beaver et al.
CLINICAL CANCER RESEARCH (2015)
Global Epidemiology of Hepatocellular Carcinoma An Emphasis on Demographic and Regional Variability
Katherine A. McGlynn et al.
CLINICS IN LIVER DISEASE (2015)
Novel drugs in clinical development for hepatocellular carcinoma
Oliver Waidmann et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
Nivolumab: targeting PD-1 to bolster antitumor immunity
Julie R. Brahmer et al.
FUTURE ONCOLOGY (2015)
Phase II study of tivantinib (ARQ 197) in patients with metastatic triple-negative breast cancer
Sara M. Tolaney et al.
INVESTIGATIONAL NEW DRUGS (2015)
A phase II study of palbociclib (PD-0332991) in adult patients with advanced hepatocellular carcinoma.
Susan Joy Littman et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Tivantinib induces G2/M arrest and apoptosis by disrupting tubulin polymerization in hepatocellular carcinoma
Qingfeng Xiang et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2015)
Immunological landscape and immunotherapy of hepatocellular carcinoma
Jesus Prieto et al.
NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY (2015)
Influence of combined CYP3A4 and CYP3A5 single-nucleotide polymorphisms on tacrolimus exposure in kidney transplant recipients: a study according to the post-transplant phase
Karim Aouam et al.
PHARMACOGENOMICS (2015)
Cabozantinib in Thyroid Cancer
Poupak Fallahi et al.
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2015)
Tivantinib (ARQ 197) affects the apoptotic and proliferative machinery downstream of c-MET: role of Mcl-1, Bcl-xl and Cyclin B1
Shuai Lu et al.
ONCOTARGET (2015)
Tivantinib (ARQ 197) efficacy is independent of MET inhibition in non-small-cell lung cancer cell lines
Antonio Calles et al.
MOLECULAR ONCOLOGY (2015)
Metabolism and Disposition of Cabozantinib in Healthy Male Volunteers and Pharmacologic Characterization of Its Major Metabolites
Steven Lacy et al.
DRUG METABOLISM AND DISPOSITION (2015)
Cabozantinib Suppresses Tumor Growth and Metastasis in Hepatocellular Carcinoma by a Dual Blockade of VEGFR2 and MET
Qingfeng Xiang et al.
CLINICAL CANCER RESEARCH (2014)
Palbociclib (PD 0332991): targeting the cell cycle machinery in breast cancer
Andrea Rocca et al.
EXPERT OPINION ON PHARMACOTHERAPY (2014)
VEGF and VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib: The ALICE-1 study
Mario Scartozzi et al.
INTERNATIONAL JOURNAL OF CANCER (2014)
The relationship of kinase insert domain receptor gene polymorphisms and clinical outcome in advanced hepatocellular carcinoma patients treated with sorafenib
You-Bing Zheng et al.
MEDICAL ONCOLOGY (2014)
Relevance of UDP-glucuronosyltransferase polymorphisms for drug dosing: A quantitative systematic review
J. C. Stingl et al.
PHARMACOLOGY & THERAPEUTICS (2014)
Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models
Osamu Tohyama et al.
JOURNAL OF THYROID RESEARCH (2014)
Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage
Yuji Yamamoto et al.
VASCULAR CELL (2014)
The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors
N. Yamamoto et al.
ANNALS OF ONCOLOGY (2013)
Risk factors for sorafenib-induced high-grade skin rash in Japanese patients with advanced renal cell carcinoma
Norihiko Tsuchiya et al.
ANTI-CANCER DRUGS (2013)
Genetic predisposition of hand-foot skin reaction after sorafenib therapy in patients with hepatocellular carcinoma
Joo Ho Lee et al.
CANCER (2013)
Cytotoxic Activity of Tivantinib (ARQ 197) Is Not Due Solely to c-MET Inhibition
Ryohei Katayama et al.
CANCER RESEARCH (2013)
Tivantinib (ARQ197) Displays Cytotoxic Activity That Is Independent of Its Ability to Bind MET
Cristina Basilico et al.
CLINICAL CANCER RESEARCH (2013)
Tivantinib: a new promising mesenchymal-epithelial transition factor inhibitor in the treatment of hepatocellular carcinoma
Lorenza Rimassa et al.
FUTURE ONCOLOGY (2013)
Cabozantinib (XL184) for the treatment of locally advanced or metastatic progressive medullary thyroid cancer
David Viola et al.
FUTURE ONCOLOGY (2013)
Expression of SLC22A1 Variants May Affect the Response of Hepatocellular Carcinoma and Cholangiocarcinoma to Sorafenib
Elisa Herraez et al.
HEPATOLOGY (2013)
Tivantinib for second-line treatment of advanced hepatocellular carcinoma: a randomised, placebo-controlled phase 2 study
Armando Santoro et al.
LANCET ONCOLOGY (2013)
Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma
Josep M. Llovet et al.
CLINICAL CANCER RESEARCH (2012)
Sorafenib Is an Inhibitor of UGT1A1 but Is Metabolized by UGT1A9: Implications of Genetic Variants on Pharmacokinetics and Hyperbilirubinemia
Cody J. Peer et al.
CLINICAL CANCER RESEARCH (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Early Sorafenib-Induced Toxicity Is Associated with Drug Exposure and UGTIA9 Genetic Polymorphism in Patients with Solid Tumors: A Preliminary Study
Pascaline Boudou-Rouquette et al.
PLOS ONE (2012)
BRCA1 and BRCA2: different roles in a common pathway of genome protection
Rohini Roy et al.
NATURE REVIEWS CANCER (2012)
Unique Metabolic Pathway of [14C]Lenvatinib after Oral Administration to Male Cynomolgus Monkey
Kazuko Inoue et al.
DRUG METABOLISM AND DISPOSITION (2012)
Targeting MET in cancer: rationale and progress
Ermanno Gherardi et al.
NATURE REVIEWS CANCER (2012)
Population pharmacokinetic analysis of sorafenib in patients with solid tumours
Lokesh Jain et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Management of Hepatocellular Carcinoma: An Update
Jordi Bruix et al.
HEPATOLOGY (2011)
PD-1 and PD-L1 upregulation promotes CD8+ T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients
Feng Shi et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth
F. Michael Yakes et al.
MOLECULAR CANCER THERAPEUTICS (2011)
c-Met: A potential therapeutic target for hepatocellular carcinoma
Jianjun Gao et al.
DRUG DISCOVERIES AND THERAPEUTICS (2011)
Association of Circulating Insulin-Like Growth Factor 1 With Hepatocellular Carcinoma: One Cross-Sectional Correlation Study
Wei-Wen Su et al.
JOURNAL OF CLINICAL LABORATORY ANALYSIS (2010)
ARQ 197-215: A randomized, placebo-controlled phase II clinical trial evaluating the c-Met inhibitor, ARQ 197, in patients (pts) with hepatocellular carcinoma (HCC)
I. Borbath et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
ARQ 197, a Novel and Selective Inhibitor of the Human c-Met Receptor Tyrosine Kinase with Antitumor Activity
Neru Munshi et al.
MOLECULAR CANCER THERAPEUTICS (2010)
The management of hepatocellular carcinoma. Current expert opinion and recommendations derived from the 10th World Congress on Gastrointestinal Cancer, Barcelona, 2008
C. Verslype et al.
ANNALS OF ONCOLOGY (2009)
UGT1A1 polymorphism and hyperbilirubinemia in a patient who received sorafenib
Judith Meza-Junco et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2009)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
The Impact of New Data in the Treatment of Advanced Hepatocellular Carcinoma
Ghassan K. Abou-Alfa et al.
CURRENT ONCOLOGY REPORTS (2008)
Association of breast cancer resistance protein/ABCG2 phenotypes and novel promoter and intron 1 single nucleotide polymorphisms
Balasubramanian Poonkuzhali et al.
DRUG METABOLISM AND DISPOSITION (2008)
Sustained complete response and complications rates after radiofrequency ablation of very early hepatocellular carcinoma in cirrhosis: Is resection still the treatment of choice?
Tito Livraghi et al.
HEPATOLOGY (2008)
Hepatocellular carcinoma (HCC): An update
Philippe Rougier et al.
SEMINARS IN ONCOLOGY (2007)
Identification of common polymorphisms in the promoter of the UGT1A9 gene: evidence that UGT1A9 protein and activity levels are strongly genetically controlled in the liver
H Girard et al.
PHARMACOGENETICS (2004)
Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survival
JM Llovet et al.
HEPATOLOGY (2003)
Share Paper
